L3MBTL2 maintains MYCN ‐amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes
Genes to Cells · 2024
DOI: 10.1111/gtc.13148 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes to Cells, 2024. Verfasst von Ryu Okada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan. Hauptthemen laut MEDLINE: Neuroblastoma, Cell Proliferation, N-Myc Proto-Oncogene Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: JSPS KAKENHI, Saitama Cancer Center, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Epigenetic alterations critically affect tumor development. Polycomb‐group complexes constitute an evolutionarily conserved epigenetic machinery that regulates stem cell fate and development. They are implicated in tumorigenesis, primarily via histone modification. Polycomb repressive complex 1 (PRC1) complexes 1–6 (PRC1.1–6) mediate the ubiquitination of histone H2A on lysine 119 (H2AK119ub). Here, we studied the functional roles of a PRC1.6 molecule, L3MBTL2, in neuroblastoma (NB) cells. L3MBTL2 ‐knockout and knockdown revealed that L3MBTL2 depletion suppressed NB cell proliferation via cell‐cycle arrest and gamma‐H2A.X upregulation. L3MBTL2‐ knockout profoundly suppressed xenograft tumor formation. Transcriptome analysis revealed suppressed cell‐cycle‐related and activated differentiation‐related pathways. Break repair meiotic recombinase recruitment factor 1 ( BRME1 ) and nuclear receptor interacting protein 3 ( NRIP3 ) were notably de‐repressed by L3MBTL2 ‐knockout. The deletion of L3MBTL2 reduced enrichment of H2AK119ub and PCGF6 at transcriptional start site proximal regions of the targets. Add‐back studies unveiled the importance of L3MBTL2‐BRME1 and ‐NRIP3 axes for NB cell proliferation. We further manifested the association of MYCN with de‐repression of NRIP3 in an L3MBTL2 ‐deficient context. Therefore, this study first revealed the significance of L3MBTL2‐ mediated gene silencing in MYCN‐amplified NB cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.
- Laboratory of Tumor Molecular Biology, Department of Graduate School of Science and Engineering, Saitama University, Saitama, Japan.
- Department of Clinical Research, Saitama Children's Medical Center, Saitama, Japan.
ORCID-Profile: Takehiko Kamijo
Förderung
- JSPS KAKENHI
- Saitama Cancer Center
- Japan Society for the Promotion of Science
Zitieren
APA
Okada, R., Takenobu, H., Satoh, S., Sugino, R. P., Onuki, R., Haruta, M., Mukae, K., Nakazawa, A., Akter, J., Ohira, M., & Kamijo, T. (2024). L3MBTL2 maintains MYCN ‐amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes. Genes to Cells. https://doi.org/10.1111/gtc.13148
Vancouver
Okada R, Takenobu H, Satoh S, Sugino RP, Onuki R, Haruta M, et al. L3MBTL2 maintains MYCN ‐amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes. Genes to Cells. 2024. doi:10.1111/gtc.13148
BibTeX
@article{Okada2024,
author = {Okada, Ryu and Takenobu, Hisanori and Satoh, Shunpei and Sugino, Ryuichi P and Onuki, Ritsuko and Haruta, Masayuki and Mukae, Kyosuke and Nakazawa, Atsuko and Akter, Jesmin and Ohira, Miki and Kamijo, Takehiko},
title = {L3MBTL2 maintains MYCN ‐amplified neuroblastoma cell proliferation through silencing NRIP3 and BRME1 genes},
journal = {Genes to Cells},
year = {2024},
doi = {10.1111/gtc.13148}
}
EUVIMED